TP53 and acute myeloid leukemia: We apply COMPASS to three datasets: a large cohort of 123 patients with acute myeloid leukemia (AML)18, 4 TP53-mutated AML patients before and after venetoclax treatment19 and 8 TP53-mutated myeloproliferative neoplasms (MPN)20.